Press Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 Jul 31 • 7 min read Revive Therapeutics announced that the FDA has approved a Phase 3 clinical trial for Bucillamine for patients with COVID-19.